Analyst Ratings for [REPL] Replimune Group, Inc.

7/23/25	Downgrades	Overweight Eq Weight	X
REPL Replimune Barclays
$3
7/23/25	Downgrades	Outperform Underperform	X
REPL Replimune BMO Capital Markets
$2
7/23/25	Downgrades	Buy Neutral	X
REPL Replimune H.C. Wainwright
7/22/25	Downgrades	Overweight Neutral	X
REPL Replimune JP Morgan
$9
7/22/25	Downgrades	Outperform Mkt Perform	X
REPL Replimune Leerink Partners
$3
7/22/25	Downgrades	Overweight Neutral	X
REPL Replimune Piper Sandler
$3
7/22/25	Downgrades	Outperform Neutral	X
REPL Replimune Wedbush
$4
6/20/25	Initiated	Overweight	X
REPL Replimune Cantor Fitzgerald
8/28/24	Initiated	Buy	X
REPL Replimune ROTH MKM
$17
4/17/23	Resumed	Overweight	X
REPL Replimune Piper Sandler
$44
11/19/21	Initiated	Overweight	X
REPL Replimune Piper Sandler
$52
10/15/21	Resumed	Buy	X
REPL Replimune BTIG Research
$60
7/23/19	Initiated	Buy	X
REPL Replimune Chardan Capital Markets
$28
7/12/19	Upgrades	Neutral Overweight	X
REPL Replimune JP Morgan
$27 $26
7/8/19	Initiated	Buy	X
REPL Replimune H.C. Wainwright
$26
4/25/19	Initiated	Outperform	X
REPL Replimune Wedbush
$24
1/23/19	Downgrades	Overweight Neutral	X
REPL Replimune JP Morgan
8/14/18	Initiated	Overweight	X
REPL Replimune JP Morgan
$26
8/14/18	Initiated	Outperform	X
REPL Replimune Leerink Partners
$25

REPL Replimune Group, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.